Advertisement
Advertisement
U.S. markets open in 8 hours 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
389.52+5.15 (+1.34%)
At close: 04:00PM EST
372.08 -17.44 (-4.48%)
After hours: 04:50PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close384.37
Open396.09
Bid0.00 x 900
Ask0.00 x 800
Day's Range388.01 - 398.00
52 Week Range249.50 - 407.93
Volume340,456
Avg. Volume250,450
Market Cap21.928B
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARGX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • argenx SE
    Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • GlobeNewswire

    argenx Enters Into Agreement To Acquire Priority Review Voucher

    Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of a single Biologics License Application (BLA), which reduces the target review period and may lead to an expedited appr

  • GlobeNewswire

    argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

    - Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod compared to intravenous (IV) administration November 22, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to

  • GlobeNewswire

    argenx to Present at Upcoming Investor Conferences

    November 7, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in November: Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day. Fireside chat on Monday, November 14, 2022 at 11:20 a.m. ET in New York, NY.Stifel 2022 Healthcare Conference. Fireside chat

Advertisement
Advertisement